What’s new

• Cohance promoters pledged 208M shares (54.36% of equity) to secure a $285M term loan from five international banks.
• The loan refinances existing debt under a repaid notes purchase agreement; additional covenants restrict remaining holdings.
• Encumbrance jumped from zero to effectively the entire promoter stake.

Why it matters

A promoter pledge of this scale is rare and signals aggressive debt restructuring. At 14.5% of market cap, the loan exposes investors to margin-call risk and potential stock overhang. The company's trailing PAT is down 93%, making debt servicing a concern.

What we’re watching

• Stock liquidity impact as pledged shares could hit the market on price triggers.
• Any further collateral calls or covenant breaches.
• Cohance's ability to service the ₹2,365 cr loan given weak earnings.

The full read

Cohance Lifesciences' promoters have done something rare. They went from zero encumbrance to pledging 54.36% of the company, 208 million shares, to secure a $285 million term loan. The money refinances old debt, but the structure is what matters. The loan, from Barclays, Deutsche Bank, BNP Paribas and others, works out to ₹2,365 crore, or 14.5% of the company's ₹15,825 crore market cap. Jusmiral Holdings and Berhyanda Limited, the two promoter vehicles, have given up their entire stakes as collateral. Covenants restrict them from selling the rest. For a company whose trailing PAT has dropped 93%, this kind of promoter-level debt transfers risk directly to public shareholders. If the stock slides, margin calls could force liquidation. Public shareholders now carry promoter debt risk on top of business risk.

Primary source: BSE · NSE